B&L to stay private for 5 years or more

Article

Bausch & Lomb (B&L) bought by Warburg Pincus last October has a long-term growth plan and will not return to the public market any time soon, said Gerry Ostrov, chief executive officer, B&L.

Rochester, NY-Bausch & Lomb (B&L) bought by Warburg Pincus last October has a long-term growth plan and will not return to the public market any time soon, said Gerry Ostrov, chief executive officer, B&L.

"Nobody has given me a specific number, but something like this is probably somewhere north of five years. Certainly, we're not talking one or two years; we are talking five-plus," Ostrov said in an interview while visiting the UK. "At some time you want to recapture the value, but it's not something I think about when I get up in the morning,

"My personal objective is to get us going at a solid double-digit growth-not immediately, but I think that is an appropriate objective," he said.

According to Ostrov, most divisions of the businesses were little affected by the economic slowdown, but laser eye surgery was suffering, since patients have to pay for procedures costing several thousand dollars out of their own pockets.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.